Unknown

Dataset Information

Programmed Cell Death Protein-1 (PD-1)-Targeted Immunotherapy for Advanced Hepatocellular Carcinoma in Real World.


ABSTRACT:

Background

Hepatocellular carcinoma (HCC) is one of the most common malignant solid tumors. Its incidence is increasing worldwide due to the dissemination of hepatitis B infection, HCV infection and nonalcoholic steatohepatitis-related HCC. For patients with advanced HCC, the available treatments are extremely limited and the prognosis is very poor. Therefore, it is urgent to discover new innovative approaches. Programmed cell death protein-1-targeted immunotherapy has shown promising results in multicenter clinical trials.

Aim

To evaluate the effectiveness and safety of anti-PD-1 agent in patients with advanced primary hepatocellular carcinoma.

Methods

A retrospective analysis of 55 patients with advanced primary hepatocellular carcinoma who had been administered ant

SUBMITTER: Cui H 

PROVIDER: S-EPMC6955600 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature